Outcomes | Statistic Types | Model 1 | Model 2 | Model 3 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
PE | 95% CI | p | PE | 95% CI | p | PE | 95% CI | p | ||
Increase in SDI | RR | 0.71 | 0.52–0.95 | 0.02 | 0.72 | 0.53–0.98 | 0.04 | 0.73 | 0.54–0.99 | 0.04 |
Flares | RR | 0.94 | 0.82–1.09 | 0.43 | 0.95 | 0.82–1.10 | 0.53 | 0.94 | 0.81–1.08 | 0.38 |
LDA achievement at yr 5 | OR | 1.96 | 1.18–3.26 | 0.009 | 2.09 | 1.25–3.52 | 0.005 | 1.88 | 1.11–3.19 | 0.02 |
Adjusted mean SLEDAI-2K over 5 yrs | ß | 0.10 | −0.19 to 0.40 | 0.49 | 0.12 | −0.18 to 0.42 | 0.45 | 0.11 | −0.20 to 0.42 | 0.49 |
Cumulative dose of GCS over 5 yrs | ß | −3.46 | −4.65 to −2.28 | < 0.0001 | −3.57 | −4.77 to −2.37 | < 0.0001 | −3.28 | −4.50 to −2.06 | < 0.0001 |
Group A: antimalarial agent intake > 60% of time; Group C: non-antimalarial agent intake. Model 1 is the primary analysis; Model 2 is the sensitivity analysis that forced musculoskeletal organ involvement into the model; Model 3 is the sensitivity analysis that forced renal organ involvement into the model. PE: parameter estimates; RR: relative risk from Poisson regression; OR from logistic regression; ß: regression coefficient from linear regression; GCS: glucocorticosteroids; LDA: low disease activity; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.